title: Antimitochondrial antibody profiles in primary biliary cirrhosis distinguish at early stages between a benign and a progressive course: a prospective study on 200 patients followed for 10 years.
abstract: In recent retrospective studies, it was shown that subtypes of antimitochondrial antibodies (AMA) can help to discriminate between a benign [only anti-M9 and/or anti-M2 positive by enzyme-linked immunosorbent assay (ELISA)] and a rather progressive course (anti-M2, -M4 and/or -M8 positive). According to different constellations of these AMA subspecificities in ELISA and complement fixation test (CFT), four AMA profiles (A-D) were defined. In 1984 we started a prospective study based on 200 PBC patients with known AMA profiles in order to correlate the antibody pattern with the clinical outcome. Progression was defined primarily as the necessity of liver transplantation and death due to hepatic failure or variceal bleeding. At entry, 18 (9%) of the 200 patients had AMA profile A (only anti-M9), 57 (29%) profile B (only anti-M2 with or without anti-M9), 74 (37%) profile C (anti-M2 in association with anti-M4/-M8 by ELISA), and 51 (26%) profile D (anti-M2/-M4/-M8 by ELISA and CFT). At the beginning of the study, 177 patients had PBC stage I/II. During the observation period of ten years, ten patients died and in 18 orthotopic liver transplantation (OLT) was performed; all these patients belonged to profile C/D. Furthermore, 44% of the patients with profile C and 31% of the patients with profile D progressed to late stages, as defined by histology and clinical manifestations such as portal hypertension and increase of bilirubin, while only one of the patients with profile B and none of the profile A-patients developed late stage PBC. A significant increase of bilirubin was observed only in C/D-patients. AMA profiles did not change during the follow-up. In conclusion, AMA profiles discriminate between a benign and a progressive course of PBC already at early stages.
authors.affiliation: Medizinische Klinik, University of Tübingen, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Klein
authors.forename: H
authors.initials: H
authors.lastname: Pointner
authors.forename: W
authors.initials: W
authors.lastname: Zilly
authors.forename: B
authors.initials: B
authors.lastname: Glässner-Bittner
authors.forename: N
authors.initials: N
authors.lastname: Breuer
authors.forename: W
authors.initials: W
authors.lastname: Garbe
authors.forename: V
authors.initials: V
authors.lastname: Fintelmann
authors.forename: J F
authors.initials: JF
authors.lastname: Kalk
authors.forename: D
authors.initials: D
authors.lastname: Müting
authors.forename: R
authors.initials: R
authors.lastname: Fischer
authors.forename: W
authors.initials: W
authors.lastname: Tittor
authors.forename: J
authors.initials: J
authors.lastname: Pausch
authors.forename: K P
authors.initials: KP
authors.lastname: Maier
authors.forename: P A
authors.initials: PA
authors.lastname: Berg
mesh_terms: D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000032:analysis*; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000175:diagnosis* / Q000401:mortality / Q000503:physiopathology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D008928:Mitochondria / Q000276:immunology*; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis
chemical_list: D001323:Autoantibodies